Human CXCR1/CXCR2 Stable Cell Line - U2OS

CXCR1 and CXCR2 are G protein-coupled receptors that bind CXC chemokine ligands, most notably interleukin-8 (CXCL8), and are central to neutrophil recruitment, angiogenesis, and tumor progression. The Human CXCR1/CXCR2 Stable Cell Line - U2OS is generated by stably expressing both human CXCR1 and CXCR2 in the U2OS osteosarcoma background, providing a dual-receptor cellular model that closely mimics the native expression pattern seen on neutrophils and certain cancer cells. This cell line is maintained under antibiotic selection to ensure stable, long-term receptor expression, and each lot is validated for receptor functionality through ligand-induced calcium flux or downstream signaling assays, with thorough quality control testing for mycoplasma and viability prior to shipment.

This cell line is ideally suited for a range of research applications, including compound screening and pharmacological characterization of small molecule antagonists or neutralizing antibodies targeting CXCR1, CXCR2, or both receptors simultaneously. It can be used to study receptor internalization, ligand selectivity, and downstream signaling pathways such as MAPK/ERK and PI3K/Akt activation. Researchers investigating inflammatory diseases like COPD, cystic fibrosis, and rheumatoid arthritis, as well as oncology applications involving tumor-associated neutrophil infiltration and metastasis, will find this tool particularly valuable. The cell line also supports the evaluation of biased agonism and allosteric modulation, enabling more nuanced drug discovery approaches. Additionally, it can be paired with functional assays such as chemotaxis or β-arrestin recruitment for a more complete picture of receptor biology. With its dual expression and proven stability, the Human CXCR1/CXCR2 Stable Cell Line - U2OS offers a robust, physiologically relevant platform for advancing chemokine receptor research from target validation through lead optimization.